DK169657B1 - Anvendelse af visse uracilnucleosider til fremstilling af et lægemiddel mod adenovirusinfektioner samt oftalmiske præparater indeholdende sådanne uracilnucleosider - Google Patents

Anvendelse af visse uracilnucleosider til fremstilling af et lægemiddel mod adenovirusinfektioner samt oftalmiske præparater indeholdende sådanne uracilnucleosider Download PDF

Info

Publication number: DK169657B1
Authority: DK; Denmark
Prior art keywords: use according; active ingredient; medicament; preparation; uracil
Prior art date: 1987-08-22

Application number

DK468288A

Other languages

Danish (da)

English (en)

Other versions

DK468288A (da

DK468288D0 (da

Inventor

John William Talbot Selway

Iii Lowrie Miller Beacham

Susan Mary Daluge

Joel Van Tuttle

Thomas Anthony Krenistky

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-08-22

Filing date

1988-08-19

Publication date

1995-01-09

1988-08-19 Application filed by Wellcome Found filed Critical Wellcome Found

1988-08-19 Publication of DK468288D0 publication Critical patent/DK468288D0/da

1989-02-23 Publication of DK468288A publication Critical patent/DK468288A/da

1995-01-09 Application granted granted Critical

1995-01-09 Publication of DK169657B1 publication Critical patent/DK169657B1/da

Links

208000010370 Adenoviridae Infections Diseases 0.000 title claims abstract description 8
238000002360 preparation method Methods 0.000 title claims description 29
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title claims description 13
239000003814 drug Substances 0.000 title claims description 11
229940035893 uracil Drugs 0.000 title claims description 11
239000002777 nucleoside Substances 0.000 title claims description 9
229940079593 drug Drugs 0.000 title claims 2
238000004519 manufacturing process Methods 0.000 title description 2
241000701161 unidentified adenovirus Species 0.000 claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
239000000203 mixture Substances 0.000 claims description 23
150000002148 esters Chemical class 0.000 claims description 15
239000002775 capsule Substances 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 11
239000000725 suspension Substances 0.000 claims description 11
-1 uracil nucleoside Chemical class 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 8
239000003889 eye drop Substances 0.000 claims description 7
229940012356 eye drops Drugs 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
229910052794 bromium Chemical group 0.000 claims description 5
239000006071 cream Substances 0.000 claims description 5
239000003885 eye ointment Substances 0.000 claims description 5
229910052731 fluorine Inorganic materials 0.000 claims description 4
239000006210 lotion Substances 0.000 claims description 4
206010060931 Adenovirus infection Diseases 0.000 claims description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
208000011589 adenoviridae infectious disease Diseases 0.000 claims description 3
239000002552 dosage form Substances 0.000 claims description 3
239000011737 fluorine Chemical group 0.000 claims description 3
229940069265 ophthalmic ointment Drugs 0.000 claims description 3
229940100654 ophthalmic suspension Drugs 0.000 claims description 3
238000011321 prophylaxis Methods 0.000 claims description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 2
229940096984 ophthalmic cream Drugs 0.000 claims 2
150000001875 compounds Chemical class 0.000 abstract description 39
230000000694 effects Effects 0.000 abstract description 9
230000003389 potentiating effect Effects 0.000 abstract description 3
239000002718 pyrimidine nucleoside Substances 0.000 abstract 1
239000004480 active ingredient Substances 0.000 description 36
239000000243 solution Substances 0.000 description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
239000003826 tablet Substances 0.000 description 12
239000004615 ingredient Substances 0.000 description 11
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
239000008101 lactose Substances 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
239000001963 growth medium Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
229940069328 povidone Drugs 0.000 description 6
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
125000000217 alkyl group Chemical group 0.000 description 5
239000002585 base Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000002609 medium Substances 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
238000002390 rotary evaporation Methods 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
235000017557 sodium bicarbonate Nutrition 0.000 description 5
239000007787 solid Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
238000013270 controlled release Methods 0.000 description 4
239000011521 glass Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
229960004063 propylene glycol Drugs 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
235000003911 Arachis Nutrition 0.000 description 3
244000105624 Arachis hypogaea Species 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
241000700605 Viruses Species 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
239000003899 bactericide agent Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
230000031709 bromination Effects 0.000 description 3
238000005893 bromination reaction Methods 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
229940079832 sodium starch glycolate Drugs 0.000 description 3
239000008109 sodium starch glycolate Substances 0.000 description 3
229920003109 sodium starch glycolate Polymers 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
229960004906 thiomersal Drugs 0.000 description 3
229940113082 thymine Drugs 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 description 2
LLKFNPUXQZHIAE-UHFFFAOYSA-N 5-(3-aminopropyl)-8-bromo-3-methyl-2h-pyrazolo[4,3-c]quinolin-4-one Chemical compound O=C1N(CCCN)C2=CC=C(Br)C=C2C2=C1C(C)=NN2 LLKFNPUXQZHIAE-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
206010001258 Adenoviral infections Diseases 0.000 description 2
UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
206010010099 Combined immunodeficiency Diseases 0.000 description 2
206010011224 Cough Diseases 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000003263 anti-adenoviral effect Effects 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000000795 conjunctiva Anatomy 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000006196 drop Substances 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
238000003682 fluorination reaction Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000000463 material Substances 0.000 description 2
239000000155 melt Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000000465 moulding Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
125000005440 p-toluyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C(*)=O)C([H])([H])[H] 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
239000006072 paste Substances 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
210000003800 pharynx Anatomy 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
208000002491 severe combined immunodeficiency Diseases 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000007858 starting material Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-BWZBUEFSSA-N 1-[(2r,4r,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-BWZBUEFSSA-N 0.000 description 1
CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
AWFYPPSBLUWMFQ-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=C2 AWFYPPSBLUWMFQ-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
BWBBMKFAGMRESB-RRKCRQDMSA-N 5-bromo-1-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](F)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 BWBBMKFAGMRESB-RRKCRQDMSA-N 0.000 description 1
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241001440741 CHER virus Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
241000739046 Cervine adenovirus Species 0.000 description 1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
208000001860 Eye Infections Diseases 0.000 description 1
206010053172 Fatal outcomes Diseases 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
244000043261 Hevea brasiliensis Species 0.000 description 1
241001428586 Human adenovirus D8 Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
206010041243 Social avoidant behaviour Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
235000009754 Vitis X bourquina Nutrition 0.000 description 1
235000012333 Vitis X labruscana Nutrition 0.000 description 1
240000006365 Vitis vinifera Species 0.000 description 1
235000014787 Vitis vinifera Nutrition 0.000 description 1
YKGNPIJNTPQMQW-UHFFFAOYSA-N [N+](=O)(O)[O-].C1(=CC=CC=C1)C1[Hg]C=CC=C1 Chemical compound [N+](=O)(O)[O-].C1(=CC=CC=C1)C1[Hg]C=CC=C1 YKGNPIJNTPQMQW-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
RWUKNUAHIRIZJG-AFEZEDKISA-M benzyl-dimethyl-[(z)-octadec-9-enyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CC1=CC=CC=C1 RWUKNUAHIRIZJG-AFEZEDKISA-M 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229960003260 chlorhexidine Drugs 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
201000010549 croup Diseases 0.000 description 1
ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000007904 elastic gelatin capsule Substances 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000002360 explosive Substances 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
208000011323 eye infectious disease Diseases 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000008098 formaldehyde solution Substances 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
238000005658 halogenation reaction Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000005457 ice water Substances 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
239000011147 inorganic material Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
150000002680 magnesium Chemical class 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000000344 soap Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000008259 solid foam Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
150000003871 sulfonates Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000005425 toluyl group Chemical group 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
239000002699 waste material Substances 0.000 description 1
210000002268 wool Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

DK468288A 1987-08-22 1988-08-19 Anvendelse af visse uracilnucleosider til fremstilling af et lægemiddel mod adenovirusinfektioner samt oftalmiske præparater indeholdende sådanne uracilnucleosider DK169657B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB878719877A GB8719877D0 (en)	1987-08-22	1987-08-22	Antiviral compounds
GB8719877		1987-08-22

Publications (3)

Publication Number	Publication Date
DK468288D0 DK468288D0 (da)	1988-08-19
DK468288A DK468288A (da)	1989-02-23
DK169657B1 true DK169657B1 (da)	1995-01-09

Family

ID=10622673

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK468288A DK169657B1 (da)	1987-08-22	1988-08-19	Anvendelse af visse uracilnucleosider til fremstilling af et lægemiddel mod adenovirusinfektioner samt oftalmiske præparater indeholdende sådanne uracilnucleosider
DK091692A DK169437B1 (da)	1987-08-22	1992-07-14	Chloreret uracilnucleosid, denne forbindelse til anvendelse mod en adenovirusinfektion, anvendelse af forbindelsen til fremstilling af et lægemiddel mod en adenovirusinfektion, farmaceutiske præparater indeholdende forbindelsen samt fremgangsmåde ti l fremstilling af forbindelsen
DK931403A DK140393D0 (da)	1987-08-22	1993-12-17	Ioderet uracilnicleosid, denne forbindelse til anvendelse mod en adenovirusinfektion, anvendelse af forbindelsen til fremstilling af et laegemiddel mod en adenovirusinfektion, farmaceutisk praeparater indeholdende forbindelsen samt fremgangsmaade til fremstilling af forbindelsen

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK091692A DK169437B1 (da)	1987-08-22	1992-07-14	Chloreret uracilnucleosid, denne forbindelse til anvendelse mod en adenovirusinfektion, anvendelse af forbindelsen til fremstilling af et lægemiddel mod en adenovirusinfektion, farmaceutiske præparater indeholdende forbindelsen samt fremgangsmåde ti l fremstilling af forbindelsen
DK931403A DK140393D0 (da)	1987-08-22	1993-12-17	Ioderet uracilnicleosid, denne forbindelse til anvendelse mod en adenovirusinfektion, anvendelse af forbindelsen til fremstilling af et laegemiddel mod en adenovirusinfektion, farmaceutisk praeparater indeholdende forbindelsen samt fremgangsmaade til fremstilling af forbindelsen

Country Status (19)

Country	Link
US (2)	US5070078A (de)
EP (2)	EP0479336A1 (de)
JP (1)	JP2634202B2 (de)
KR (1)	KR890003382A (de)
AT (1)	ATE82681T1 (de)
AU (1)	AU613659B2 (de)
CA (1)	CA1333361C (de)
DE (1)	DE3876174T2 (de)
DK (3)	DK169657B1 (de)
ES (1)	ES2052732T3 (de)
GB (1)	GB8719877D0 (de)
GR (1)	GR3006510T3 (de)
HU (1)	HU211666A9 (de)
IE (2)	IE940696L (de)
MX (1)	MX9203416A (de)
NZ (1)	NZ225881A (de)
PT (1)	PT88306B (de)
SG (1)	SG26364G (de)
ZA (1)	ZA886182B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8719877D0 (en) *	1987-08-22	1987-09-30	Wellcome Found	Antiviral compounds
GB8726136D0 (en) *	1987-11-07	1987-12-09	Wellcome Found	Therapeutic nucleosides
US5157114A (en) *	1988-08-19	1992-10-20	Burroughs Wellcome Co.	2',3'-dideoxy-3'-fluoro-5-ethyngluridine
WO1990003978A1 (en) *	1988-10-03	1990-04-19	Stichting Rega Vzw	5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application
GB9003543D0 (en) *	1990-02-16	1990-04-11	Wellcome Found	Therapeutic nucleosides
US5166327A (en) *	1990-07-31	1992-11-24	Yuki Gosei Kogyo Co., Ltd.	Process for producing 3'-deoxy-3-'-fluorothymidine
JP2804184B2 (ja) *	1991-05-14	1998-09-24	シャープ株式会社	ファクシミリ装置
DE4121001C1 (de) *	1991-06-21	1993-05-06	Max-Delbrueck-Centrum Fuer Molekulare Medizin Berlin-Buch, O-1115 Berlin, De
US5341595A (en) *	1992-06-15	1994-08-30	Environmental Growth Chambers	Environmental chamber for plant growth analysis
GB9309787D0 (en) *	1993-05-12	1993-06-23	Rhone Poulenc Chemicals	Purification of fluoronucleosides
ES2121204T3 (es) *	1993-05-12	1998-11-16	Rhodia Limited	Preparacion de fluoro-nucleosidos e intermedios para su uso en ella.
SE503787C2 (sv) *	1994-12-07	1996-09-02	Electrolux Ab	Anordning för att tillhandahålla kylda eller frysta varor
US5690202A (en) *	1996-04-15	1997-11-25	Myers; John E.	Overrunning clutch mechanism
US6514979B1 (en)	1999-03-03	2003-02-04	University Of Maryland Biotechnology Institute	Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
US6855561B2 (en) *	2001-09-10	2005-02-15	Quidel Corporation	Method for adding an apparent non-signal line to a lateral flow assay
US20030236218A1 (en) *	2002-06-12	2003-12-25	Uckun Fatih M.	Aryl phosphate derivatives of d4T with selective activity against adenovirus and HIV
CN1302779C (zh) *	2002-06-27	2007-03-07	美迪维尔公司	含有阿巴卡韦和阿洛夫定的药物制剂及其用途
CN1248266C (zh) *	2002-12-26	2006-03-29	邱智铭	一种转动式电开关结构
US7160537B2 (en) *	2003-12-15	2007-01-09	Siemens Medical Solutions Usa, Inc.	Method for preparing radiolabeled thymidine having low chromophoric byproducts
US20050131224A1 (en) *	2003-12-15	2005-06-16	Cti Pet Systems, Inc.	Method for preparing radiolabeled thymidine
RU2628456C1 (ru) *	2016-06-29	2017-08-17	Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран)	Новые пиримидиновые ингибиторы репликации аденовируса человека

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE103241C (de) *
GB1251828A (de) *	1968-12-19	1971-11-03
DE1913384C2 (de) *	1968-12-20	1982-12-16	Akademie Der Wissenschaften Der Ddr, Ddr 1199 Berlin	1-(2',3'-Didesoxy-3'-fluor-β-D-xylofuranosyl)-thymin, Verfahren zu seiner Herstellung und dieses enthaltende Cytostatica
GB1189973A (en) *	1969-02-14	1970-04-29	Akad Wissenschaften Ddr	Cytostatically-Active 2',3'-Didesoxy-3'-Fluoropyrimidine-Nucleosides
US3775397A (en) *	1969-11-12	1973-11-27	Akad Wissenschaften Ddr	Novel cytostatic 2',3'-dideoxy-3'-fluoropyrimidine-nucleosides
DD103241A1 (de) *	1972-12-12	1974-01-12
WO1987000719A1 (fr) *	1985-07-23	1987-01-29	Wolf, Karl	Circuit pour l'amorcage et le fonctionnement d'au moins une lampe a decharge de faible ou de haute pression avec oscillations a frequence elevee
DE3650741T2 (de) *	1985-09-17	2000-10-12	The Wellcome Foundation Ltd., Greenford	Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
US4710492A (en) *	1986-06-23	1987-12-01	Yale University	3'-azido-2',3'-dideoxy-5-halouridine and its use in treating patients infected with retroviruses
SE8602981D0 (sv) *	1986-07-04	1986-07-04	Astra Laekemedel Ab	Novel medicinal use
DD279407A1 (de) *	1986-07-24	1990-06-06	Akad Wissenschaften Ddr	Verfahren zur herstellung eines mittels gegen aids
EP0332626A1 (de) *	1986-11-21	1989-09-20	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Zubereitungen zur behandlung viraler infektionen bei menschen
US4880782A (en) *	1986-11-21	1989-11-14	Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V.	Method of treating viral infections in humans and compositions therefor
GB8719877D0 (en) *	1987-08-22	1987-09-30	Wellcome Found	Antiviral compounds
WO1990003978A1 (en) *	1988-10-03	1990-04-19	Stichting Rega Vzw	5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application

1987
- 1987-08-22 GB GB878719877A patent/GB8719877D0/en active Pending
1988
- 1988-08-19 KR KR1019880010598A patent/KR890003382A/ko not_active Ceased
- 1988-08-19 JP JP63206229A patent/JP2634202B2/ja not_active Expired - Lifetime
- 1988-08-19 IE IE940696A patent/IE940696L/xx unknown
- 1988-08-19 AU AU21429/88A patent/AU613659B2/en not_active Ceased
- 1988-08-19 IE IE253388A patent/IE63655B1/en not_active IP Right Cessation
- 1988-08-19 NZ NZ225881A patent/NZ225881A/en unknown
- 1988-08-19 PT PT88306A patent/PT88306B/pt not_active IP Right Cessation
- 1988-08-19 ZA ZA886182A patent/ZA886182B/xx unknown
- 1988-08-19 US US07/234,215 patent/US5070078A/en not_active Expired - Fee Related
- 1988-08-19 ES ES88307689T patent/ES2052732T3/es not_active Expired - Lifetime
- 1988-08-19 EP EP91120810A patent/EP0479336A1/de not_active Withdrawn
- 1988-08-19 EP EP88307689A patent/EP0305117B1/de not_active Expired - Lifetime
- 1988-08-19 CA CA000575197A patent/CA1333361C/en not_active Expired - Fee Related
- 1988-08-19 DK DK468288A patent/DK169657B1/da not_active IP Right Cessation
- 1988-08-19 AT AT88307689T patent/ATE82681T1/de not_active IP Right Cessation
- 1988-08-19 SG SG1995904231A patent/SG26364G/en unknown
- 1988-08-19 DE DE8888307689T patent/DE3876174T2/de not_active Expired - Fee Related
1992
- 1992-06-25 MX MX9203416A patent/MX9203416A/es unknown
- 1992-07-14 DK DK091692A patent/DK169437B1/da not_active IP Right Cessation
- 1992-12-11 GR GR920402878T patent/GR3006510T3/el unknown
- 1992-12-24 US US07/996,727 patent/US5376644A/en not_active Expired - Fee Related
1993
- 1993-12-17 DK DK931403A patent/DK140393D0/da not_active IP Right Cessation
1995
- 1995-06-30 HU HU95P/P00645P patent/HU211666A9/hu unknown

Also Published As

Publication number	Publication date
HU211666A9 (en)	1995-12-28
EP0479336A1 (de)	1992-04-08
SG26364G (en)	1995-09-18
AU2142988A (en)	1989-05-25
DK169437B1 (da)	1994-10-31
ZA886182B (en)	1990-04-25
JP2634202B2 (ja)	1997-07-23
IE940696L (en)	1989-02-22
CA1333361C (en)	1994-12-06
NZ225881A (en)	1991-03-26
PT88306B (pt)	1995-12-29
IE882533L (en)	1989-02-22
EP0305117B1 (de)	1992-11-25
DK140393A (da)	1993-12-17
EP0305117A2 (de)	1989-03-01
IE63655B1 (en)	1995-05-31
ES2052732T3 (es)	1994-07-16
DE3876174T2 (de)	1993-04-01
DK91692D0 (da)	1992-07-14
KR890003382A (ko)	1989-04-14
US5070078A (en)	1991-12-03
DK91692A (da)	1992-07-14
GR3006510T3 (de)	1993-06-30
EP0305117A3 (en)	1989-12-27
DK468288A (da)	1989-02-23
JPS6468325A (en)	1989-03-14
MX9203416A (es)	1992-07-01
US5376644A (en)	1994-12-27
AU613659B2 (en)	1991-08-08
PT88306A (pt)	1989-06-30
DE3876174D1 (de)	1993-01-07
DK140393D0 (da)	1993-12-17
ATE82681T1 (de)	1992-12-15
DK468288D0 (da)	1988-08-19
GB8719877D0 (en)	1987-09-30

Legal Events

Date	Code	Title	Description
1995-01-09	B1	Patent granted (law 1993)
1997-04-14	PBP	Patent lapsed

Publication	Publication Date	Title
DK169657B1 (da)	1995-01-09	Anvendelse af visse uracilnucleosider til fremstilling af et lægemiddel mod adenovirusinfektioner samt oftalmiske præparater indeholdende sådanne uracilnucleosider
US4861759A (en)	1989-08-29	Antiviral compositions and methods
CS342591A3 (en)	1992-04-15	Pharmaceuticals comprising 1-(beta-d-arabinofuranosyl)-5-propinyluracil
SK95193A3 (en)	1994-01-12	Antiviral nucleoside combination
JPS61280500A (ja)	1986-12-11	ヌクレオシド化合物
JPH06505725A (ja)	1994-06-30	５−フルオロ−２’−デオキシ−３’−チアシチジンのｂ型肝炎治療への使用
JPS63239294A (ja)	1988-10-05	新規アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
CA2065279A1 (en)	1991-01-18	Antiviral pyrimidine nucleosides
NO156690C (no)	1987-11-04	Analogifremgangsmaate ved fremstilling av terapeutisk aktive indanderivater.
US5254539A (en)	1993-10-19	Method of treating HIV with 2',3'-dideoxyinosine
FI91156C (fi)	1994-05-25	Menetelmä uusien terapeuttisesti käyttökelpoisten neplanosiinijohdannaisten valmistamiseksi
EP1706405B1 (de)	2009-03-04	4'-substituierte carbovir- und abacavir-derivate sowie verwandte verbindungen mit hiv- und hcv-antiviraler wirkung
CZ123293A3 (en)	1994-03-16	2'-deoxy-2',2'-difluoro-(2,6,8-substituted)purinenucleoside derivative, pharmaceutical preparation containing thereof and an intermediate for its preparation
CN116217621B (zh)	2023-08-11	一种核苷类双前药、合成方法及应用
JPS59167517A (ja)	1984-09-21	単純ヘルペスウイルス感染症用組成物及び治療方法
US5026732A (en)	1991-06-25	Use of avarone for the control of AIDS and ARC
TWI905225B (zh)	2025-11-21	感冒劑及抗病毒劑
EP0082667A1 (de)	1983-06-29	Pharmazeutische Zusammensetzungen
CA1333392C (en)	1994-12-06	Antiviral compounds
JPS5826896A (ja)	1983-02-17	デオキシウリジン誘導体、それらの製法およびそれらを含有する医薬組成物
TW212138B (de)	1993-09-01
JPS63107924A (ja)	1988-05-12	抗レトロウイルス剤
JPH0283325A (ja)	1990-03-23	抗ウイルス剤
JPS63310826A (ja)	1988-12-19	抗ウィルス剤
EP0132540A1 (de)	1985-02-13	Antiviruszusammensetzungen